Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
Annals of Clinical and Translational Neurology · 2025
DOI: 10.1002/acn3.70165 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Craig M McDonald und 27 weiteren Autor:innen. Beteiligte Einrichtung: University of California Davis Health, Sacramento, California, USA. Hauptthemen laut MEDLINE: Carbamates, Histone Deacetylase Inhibitors, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIH HHS, Italfarmaco.
Abstract (Originalsprache)
Objectives
This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD).
Methods
The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS]), receiving givinostat or placebo, or were successfully screened but not randomized into EPIDYS. All receive givinostat oral suspension open‐label at a flexible, weight‐based dose in addition to systemic corticosteroids, and attend visits every 4 months.
Results
A total of 194 patients are included in the current analyses, with a mean duration of givinostat exposure (excluding use in prior studies) of 559.6 days (SD 373.0); when including use in the prior studies, the maximum exposure to givinostat was > 8 years. Although the majority of patients reported ≥ 1 adverse event (169/194 [87.1%]), most were mild/moderate in severity, and the safety profile of givinostat was consistent with prior studies. Post hoc comparisons with natural history datasets (ImagingDMD and CINRG) suggest, in propensity matched populations, givinostat added to systemic corticosteroids significantly delayed the loss of the ability to rise from the floor, the loss of the ability to complete the 4‐stair climb test, and the loss of ambulation (by medians of 2.0–3.3 years; all nominal p < 0.05).
Interpretation
Overall, the safety and tolerability of long‐term administration of givinostat in patients with DMD was consistent with previous studies. Comparisons with natural history data suggest that givinostat delays the occurrence of major disease progression milestones. Trial Registration EudraCT number: 2017‐000397‐10; ClinicalTrials.gov identifier: NCT03373968
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California Davis Health, Sacramento, California, USA.
- The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
- Clinic for Neurology and Psychiatry for Children and Youth, Belgrade, Serbia.
- Division of Neurology, Connecticut Children's, Hartford, Connecticut, USA.
- Division of Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Center of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, Genova, Italy.
Förderung
- NIAMS NIH HHS
- NIH HHS
- Italfarmaco
- National Institutes of Health
Zitieren
APA
McDonald, C. M., Guglieri, M., Vučinić, D., Acsadi, G., Brandsema, J. F., Bruno, C., Finanger, E. L., Harper, A., Lobato, M. L., Masson, R., Muelas, N., Munell, F., Nevo, Y., Péréon, Y., Phan, H., Sansone, V. A., Scoto, M., Willis, T., Finkel, R. S., …, & ImagingDMD Investigators (2025). Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70165
Vancouver
McDonald CM, Guglieri M, Vučinić D, Acsadi G, Brandsema JF, Bruno C, et al. Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70165
BibTeX
@article{McDonald2025,
author = {McDonald, Craig M and Guglieri, Michela and Vučinić, Dragana and Acsadi, Gyula and Brandsema, John F and Bruno, Claudio and Finanger, Erika L and Harper, Amy and Lobato, Mercedes Lopez and Masson, Riccardo and Muelas, Nuria and Munell, Francina and Nevo, Yoram and Péréon, Yann and Phan, Han and Sansone, Valeria A and Scoto, Mariacristina and Willis, Tracey and Finkel, Richard S and Vandenborne, Krista and Cazzaniga, Sara and Montrasio, Silvia and Alessi, Federica and Bettica, Paolo and Mercuri, Eugenio and Givinostat Study 51 Investigators, Givinostat Study 51 Investigators and Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators, Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS) Investigators and ImagingDMD Investigators, ImagingDMD Investigators},
title = {Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
doi = {10.1002/acn3.70165}
}
EUVIMED